Skip to content
Eyeing A Challenge to a Blockbuster episode artwork

Jul 10, 2025 40 min

Eyeing A Challenge to a Blockbuster

from RARECast

Tepezza became an instant blockbuster when it hit the market as the first targeted therapy for thyroid eye disease, a rare autoimmune condition that causes eyes to bulge, vision problems, and can lead to long-term damage to the eyes. The success of Tepezza drove Amgen’s $27.8 billion acquisition of Horizon Therapeutics, announced at the end of 2022. Now, Viridian Therapeutics is developing veligrotug, a potential challenger to Tepezza. It’s betting that its demonstrated efficacy, greater dosing convenience, and data showing an ability to resolve double vision associated with thyroid eye disease will make it a fierce competitor. We spoke to Steve Mahoney, CEO of Viridian, about the complexities of thyroid eye disease, the challenges of living with the condition, and why veligrotug has the potential to provide a new alternative for people living with the condition.

Episode details come from the podcast's RSS feed.

Embed this episode

Steve Mahoney, CEO of Viridian Therapeutics, discusses the complexities of thyroid eye disease, the challenges of living with the condition, and why veligrotug has the potential to provide a new alternative for people living with the condition.

Ready to play

Eyeing A Challenge to a Blockbuster

0:00 40:04

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of RARECast?

This episode is 40 minutes long.

When was this RARECast episode published?

This episode was published on July 10, 2025.

Can I download this RARECast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.